Indications and Management of Trelegy Ellipta Triple Therapy for COPD

Patient Selection and Indication

Adults with severe chronic obstructive pulmonary disease who continue to experience repeated exacerbations despite optimal dual bronchodilator therapy should be considered for triple therapy with fluticasone furoate/umeclidinium/vilanterol. 1

Trelegy Ellipta is delivered via the ELLIPTA dry‑powder inhaler; proper inhaler technique must be verified before initiating or escalating therapy. 2
Approximately three‑quarters of COPD patients make critical errors with inhaler use, underscoring the need for technique assessment prior to therapy escalation. 2
A confirmed diagnosis of COPD and exclusion of alternative respiratory conditions are required before starting triple therapy. 2
Current inhaler technique should be reassessed before attributing treatment failure to medication inefficacy. 2

If symptoms persist on the standard dose, referral for home nebulizer therapy with high‑dose bronchodilators should be considered after formal respiratory specialist evaluation. 2
Addition of theophylline may be contemplated in severe disease, with careful monitoring for adverse effects. 2
Exacerbation management should be optimized using increased bronchodilator dosing, short‑course oral corticosteroids (e.g., 30 mg daily for one week), and antibiotics when indicated. 2
Non‑pharmacologic interventions—including pulmonary rehabilitation, nutritional support for underweight patients, and vaccination—should be incorporated into the comprehensive care plan. 2